Edison issues initiation on BONESUPPORT (BONEX) | Financial Buzz

Edison issues initiation on BONESUPPORT (BONEX)

LONDON, U.K., June 21, 2018 (GLOBE NEWSWIRE) — BONESUPPORT is commercialising synthetic bone graft substitutes. The company invests in R&D to support continued development of innovative products that command premium pricing and differentiate them in a competitive market. Following recent issues with the exclusive, long-standing distributor in the US, BONESUPPORT terminated the agreement and US sales are expected to recover via an independent distributor network and a more hands-on approach to growing sales. After a successful IPO in June 2017 raising SEK520m, the company is well funded. We value BONESUPPORT at SEK1.13bn or SEK22.2/share.

Based on our DCF model, we value BONESUPPORT at SEK1.13bn or SEK22.2/share. Our model reflects organic growth in existing markets, for which we estimate that existing funds are sufficient to reach profitability by 2021. We also include risk-adjusted (70%) CERAMENT G profits in the US market from 2021. Continued strong sales growth in Europe, rebound in the US and results from the CERTiFy trial are key share price drivers in the near term.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44 (0)20 3077 5728
Healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn      https://www.linkedin.com/company/edison-investment-research 
Twitter     www.twitter.com/Edison_Inv_Res 
YouTube     www.youtube.com/edisonitv

Primary Logo